Clinical effect of percutaneous transluminal angioplasty for the treatment of diabetic lower extremity arterial disease
10.11659/jjssx.11E015125
- VernacularTitle:经皮腔内血管成形术治疗糖尿病下肢动脉血管病变的临床疗效观察
- Author:
Rui ZHANG
;
Qiang TONG
;
Jing XU
;
Hui WANG
;
Houdi ZHOU
;
Jun CHENG
- Publication Type:Journal Article
- Keywords:
percutaneous transluminal angioplasty;
diabetes;
lower extremity artery disease
- From:Journal of Regional Anatomy and Operative Surgery
2016;(1):21-24
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of percutaneous endovascular angioplasty ( PTA) for the treatment of diabetic lower extremity arterial disease( LEAD) , so as to provide a reference for the selection of the best treatment for diabetic lower extremity arterial dis-ease(LEAD). Methods In this parallel study, totally 60 patients were equally divided into the control group and the intervention group. The control group were treated by the conventional method, and the intervention group were treated by percutaneous endovascular angioplasty (PTA). The changes of ankle brachial index (ABI),average blood flow velocity of dorsalis pedis,pulsation index(PI) and the maximum walking distance were observated in 12 weeks and 24 weeks after the treatment. Results Compared with the control group, the ankle brachi-al index ( ABI) , average blood flow velocity of dorsalis pedis, pulsation index ( PI) and the maximum walking distance in the intervention group were significantly improved 12 weeks and 24 weeks after treatment, and the difference between the two groups was statistically signifi-cant (P<0. 05). And compared with thses data before treatment in the intra-group comparison, there were statistically significant difference (P<0. 05). However, the changes in 24 weeks and 12 weeks after treatment in the same group showed no significant difference (P>0. 05). Conclusion Percutaneous endovascular angioplasty ( PTA) is better than traditional drug therapy in the treatment of diabetic lower extremity arterial disease( LEAD) . It is a feasible clinical treatment of lower extremity arterial disease( LEAD) .
